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Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is an RNA virus which
belongs to the family Arteriviridae. Since its emergence in the late 1980’s and early 1990’s,
PRRSV has had a major economic effect on the swine industry. The most notable effects of this
disease are respiratory distress in piglets and late-term pregnancy failures in sows. To track and
control spread of this disease, the industry must be able determine which animals have been
naturally infected with PRRSV as this contributes to major disease outbreaks and localized
pandemics. While vaccines help control the spread of a disease, they also interfere with
tracking of disease outbreaks. A DIVA test allows for the differentiation of animals which were
naturally infected from those that were infected via immunization and is used in conjunction
with a vaccine. Our primary objective was to develop rabbit polyclonal and mouse monoclonal
antibodies against a highly immunogenic, heterologous gene not native to PRRSV to be used as
reagents for a PRRSV specific DIVA (Differentiating Infected from Vaccinated Animals) test. To
start the project, non-structural protein PRRSV-NSP2 was modified to include an immune
marker (S-tag genetic marker) to be used as a positive selection tag that allows for the

diagnostic detection of the vaccine virus strain. This protein was cloned into a plasmid
expression vector, expressed in E. coli bacteria, and purified in order to be used as an antigen to
immunize mice and rabbits. The immunization of rabbits was effective for producing polyclonal
antibodies to be used for further research and diagnostic purposes, while the immunization of
the mice was used to generate monoclonal antibodies through the formation of hybridoma
cells. A hybridoma is produced by fusing splenic B cells from the immunized mice with mouse
tumor cells (NS-1 myeloma). These hybridomas produced monoclonal antibodies which were
expected to be specific to PRRSV MLVΔ23-S tag epitopes. These monoclonal antibodies were
characterized and their ability to recognize PRRSV MLVΔ23-S tag epitopes was assessed via
enzyme linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and Western
blot assay. Overall, we recovered eighteen separate hybridoma cell lines which were
immunoreactive via ELISA and Western blotting. Eight of these were also immunoreactive via
IFA. We also obtained approximately 75 mL of anti-PRRSV S-tag specific rabbit polyclonal
antisera. These resulting monoclonal and polyclonal antibodies will be useful to develop a DIVA
test for the veterinary diagnostic industry. This test can be used to monitor the effectiveness of
the PRRSV vaccine and spread of the disease in order to assist in reducing the major economic
impact of PRRSV on the swine industry.

Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV), discovered in the United
States in 1987, is a single-stranded, positive-sense RNA virus from the family Arteriviridae [1].
Its genome contains a minimum of 10 open reading frames (ORFs). ORF 1a and ORF 1b make up

¾ of the viral genome and produce 14 non-structural proteins after enzymatic cleavage while
ORFs 2-7 code for structural proteins (Figure 1) [2]. This disease causes respiratory distress in
piglets and late-term pregnancy failures. It can be transmitted through direct contact with
placental and intranasal membranes and replicates in regional macrophages, which then
spreads throughout the body and causes viremia and infection of other macrophages [1]. This
disease is economically devastating to the swine industry, even more so than diseases that
previously impacted it. PRRSV is estimated to cost the swine industry around 560 million dollars
annually compared to classical swine fever (364 million) and pseudorabies virus (36 million).
This loss is due to a significant reduction in the number of piglets which survive to weaning as
well as an increase in secondary infections, reduction in growth efficiency, and even death in
growing-finishing pigs [3]. The substantial economic effects of PRRSV necessitate a need for
improved technologies to study and manage the disease’s effects in order to move closer to the
hopeful eradication of the disease.

S-tag

Figure 1. Organization of porcine reproduction and respiratory syndrome virus (PRRSV) genome.
ORF1a and 1b code for 14 non-structural proteins, including our protein of interest: non-structural
protein 2 (NSP2) in which we inserted a heterologous S-tag sequence for virus identification. [2]

An important tool used in the eradication of disease is vaccines, which can be incredibly
useful to decrease or even prevent infection for many diseases. The eradication of a disease
also relies on comprehensive and accurate serological surveillance of that disease within a
population. However, vaccinations can hinder serological surveillance of a disease as many
vaccines induce an identical antibody response to that of natural infection. This issue can be
resolved through the development and usage of a DIVA vaccine [4][5]. A DIVA vaccine is
accompanied by a diagnostic test which allows the veterinary industry to determine which
animals were naturally infected versus those that received a vaccine consisting of a modified
live virus. This is useful for continued epidemiological investigation of PRRSV among the porcine
population, and also enables continuous monitoring of the safety and success of the vaccine
[6].
The first step in the development of a DIVA test is to develop diagnostic detection
reagents. Our primary objective was to develop rabbit polyclonal and mouse monoclonal
antibodies against a highly immunogenic, heterologous gene not native to PRRSV to be used as
reagents for a PRRSV specific DIVA test. To develop the monoclonal antibodies necessary for a
DIVA test, we created hybridomas which produce monoclonal antibodies against PRRSV
MLVΔ23-S tag protein [7]. A common method used to generate a DIVA vaccine and test is to
take a protein from a virus and delete a portion of it, otherwise known as a negative selection
marker [8]. Our technique differs from typical methods as we inserted an immune marker (an
mRNA sequence that codes for a 15 amino acid S-tag genetic marker peptide sequence), known
as a positive selection tag, into the genome of the PRRSV-NSP2 protein (Figure 1). The genetic
sequence was then cloned into an expression vector which allowed it to be transformed in E.

coli bacteria. The bacteria produced the S- tag protein which was then purified & used as
antigen for immunization of mice and rabbits. After a 68-day immunization regimen, we
harvested splenic B-cells from mice and fused them with NS-1 myeloma cells to form
hybridomas which produced our monoclonal antibodies.
Monoclonal antibodies are monovalent antibodies which are derived from a single Blymphocyte and have specific affinity for the same epitope. The most effective way to obtain
these antibodies is by using a technique involving hybridoma formation [9]. Hybridomas were
first successfully formed and used for monoclonal antibody production in 1975 by George
Kohler and Cesar Milstein [10]. The process of forming a hybridoma starts with the
immunization of a species with the antigen of interest. The B-lymphocytes from the immunized
animal are then harvested from its spleen and fused with an immortal myeloma cell line. The
myeloma cells lack the Hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene [9].
HGPRT is expressed when the hybridomas are placed in selective medium. This medium
contains hypoxanthine-aminopterin-thymidine (HAT), which blocks unfused myeloma cells from
using their salvage pathway to produce nucleotides due to their missing HGPRT gene. However,
the myeloma cells which fused with B-cell inherit the HGPRT gene from the B-cells and are able
to use it to produce pyrimidine nucleotides. The result of using this process is that only the
hybridomas survive [11].
Initially, the culture of hybridomas contains a variety of B-lymphocytes, each producing
antibodies for different antigens. This provides a polyclonal mixture of antibodies. In order to
isolate the desired monoclonal antibody, the hybridomas are diluted into a multi-well culture
plate. This allows a greater likelihood that each well will contain a monoclonal hybridoma. Each

well is then screened individually to determine if it contains antibodies specific to the target
antigen. The positive wells are then recloned and undergo secondary screening to ensure they
still have specificity for the antigen. The hybridomas can then be expanded to produce an
abundance of monoclonal antibodies [9].
Monoclonal antibodies can be utilized in many ways. Most applicable to our research is
their use in diagnostic tests, specifically indirect immunofluorescence assay (IFA), enzymelinked immunosorbent assay (ELISA), and Western blot. For an IFA, mammalian cells are
transfected with DNA for the target antigen. The antibodies are put on the cells along with a
fluorescent dye where they bind transfected cells. This allows the visualization of these cells
using a fluorescent microscope. Instead of using DNA like in the IFA, an ELISA uses proteins. A
specific protein from the target pathogen is attached to the surface of a plate and then
antibodies specific to that protein are applied. These antibodies bind the protein. Next, a
secondary antibody which is linked to an enzyme is plated which binds the primary antibody.
Finally, a reagent containing the substrate specific to the enzyme on the secondary antibody is
plated which results in a measurable color change. A Western blot assay is performed by first
running a linear protein on a gel using electrophoresis. Next, primary antibodies are added to
the gel which bind to the protein. Enzyme-conjugated secondary antibodies are added to the
membrane next which bind to the primary antibodies and can be visualized via a color change
imparted by the addition of a chromogenic substrate [12]. Using monoclonal antibodies in the
context of IFA, ELISA, and Western blot allows us to evaluate the immunoreactivity of the
antibodies which will then be used to validate a DIVA test for PRRSV.

Materials and Methods
Expression of the PRRSV NSP2 S-tag protein
The 660-nucleotide codon optimized region of the PRRSV NSP2 genome which
contained the S-tag gene was cloned into an expression vector (pET-28a, Novagen; Madison,
WI) and then transformed into E. coli (BL21-Codon Plus DE3 RP competent) for expression of
the protein. 50 μL of the transformed cells were plated onto agar plates and incubated at 37°C
overnight. The next day, colonies were placed in 2X yeast extract tryptone (YT) culture media.
Once the cultures were grown to an optical density of 0.5 at 37°C, then expression was induced
using a 1.0 mM concentration of isopropyl β-D-1-thiogalactopyranoside (IPTG). This induced
transcription of the Lac operon and the downstream NSP2 protein. The E. coli were incubated
for an addition 8 hours at 37°C [12].
After the additional incubation, the bacteria were strained out and centrifuged at
10,000 x g for 10 minutes at 4°C to obtain a pellet. Resuspension of the pellet was achieved
using 50 mL of lysis buffer solution (B-PER, Pierce, Rockford, IL) which was then incubated at
room temperature (20°C) for 20 minutes. It was then centrifuged at 10,000 x g to separate
soluble and insoluble proteins. The protein was denatured with 8 M urea and purified using
nickel-NTA affinity column chromatography. Elutions were collected, confirmed using SDSPAGE, then frozen at -80°C. Western blotting using a 6X histidine specific monoclonal antibody
(Novagen; Madison, WI) was used in order to confirm the protein. The resulting NSP2 S-tag
protein was used to immunize mice and rabbits [12].

Development of enzyme-linked immunosorbent assay for hybridoma screening
An Immulon 1B medium binding 96 well micro-titer plate was coated with PRRSV NSP2
S-tag protein and a heterologous HIS-tag control (SVS VP2 12-15-15). PRRSV NSP2 S-tag was
diluted 1:2000 in antigen coating buffer (ACB) and 100 μL was added to odd numbered wells.
SVS VP2 12-15-15 was also diluted 1:1500 in ACB and 100 μL was added to even numbered
wells. The plate was allowed to incubate at 37°C for 1 hour. A 5% nonfat dry milk (Shurefine;
Skukie, IL) and PBS solution was made as a blocking antibody diluent buffer (BAD) and 200 μL
was applied to each well. This was incubated at 4°C overnight. In the morning, the plate was
washed four times with PBS + 0.05% Tween 20 (PBST).
To screen the hybridomas, 60 μL of undiluted cell culture supernatant was added to
each well. This was incubated for 1 hour at room temperature and then the plate washed four
times with PBST. 100 μL of a goat anti-mouse, IgG, IgA, IgM-HRP conjugate (MP-Bio; Santa Ana,
CA) diluted 1:5000 in BAD was added to each well and the plate was incubated for 1 hour at
room temperature. TMB chromogenic substrate (VMRD; Whitman Country, WA) was removed
from the fridge and allowed to warm to room temperature. It was then tested via a 1:150
dilution of the enzyme-containing secondary and displayed a clear blue color indicating that it
worked. The plate was washed four times in PBST and then 100 μL of TMB was added to each
well. Finally, the reaction was stopped using 100 μL of 2N H2SO4 in each well and the optical
densities were measured using an ELx800 microplate reader (BioTek Instruments Inc.;
Winooski, VT) at 450 nm.

Development of Western blot for hybridoma screening
Color chromogen development Western blotting was used to identify the PRRSV NSP2 Stag protein. For this method, the PRRSV NSP2 S-tag antigen was diluted 1:6 in Laemelli sample
buffer which was then heat treated at 97°C for 10 minutes. An SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) of the samples was completed at 120 Volts for 75 minutes using an
8% polyacrylamide gel (Invitrogen; Carlsbad, CA). Electroblot was then used at 125 Volts for 1
hour to transfer the protein gel to a nitrocellulose membrane (Fischer Scientific; Hampton, NH).
The membrane was blocked overnight using BAD at 4°C. In the morning, cell culture
supernatant diluted 1:25 in BAD plus 0.1% Bovine Serum Albumin (BSA) and allowed to
incubate for 2 hours at room temperature. The membrane was washed in PBST three separate
times, each for 5 minutes. Then, a goat anti-mouse IR secondary antibody was diluted 1:5000 in
BAD and was incubated at room temperature for 1 hour. The membrane was again washed in
PBST three separate times, each for 5 minutes. Finally, chloro-1-naphol was used as the
chromogenic substrate to detect the protein.
Development of immunofluorescent assay for hybridoma screening
To develop an immunofluorescent assay for PRRSV MLVΔ23-S tag hybridoma screening,
African green money kidney derived cells (MARC-145 cells) were seeded onto Immulon 1B
medium binding 96 well micro-titer plates (Thermo Labsystems, Franklin, MA) and incubated
for 48 hours. They were then infected with the PRRSV MLVD23S virus strain which was
modified to contain the S-tag. The infected MARC-145 cells were incubated for 24 hours and
then fixed with 80% acetone.

To screen hybridomas, 50 μL of undiluted cell culture supernatant was added to each
well and then the plate was incubated with CO2 for 1 hour at 37°C. Next, the plate was washed
three times with PBS and 100 μL of FITC (MP Bio; Santa Ana, CA) diluted PBS-BN + 1% Sodium
Azide was added to each well. The plate was incubated for 1 hour at 37°C and then washed an
additional three times with PBS. A few microliters of PBS were left in the bottom of each well
after washing to ensure the cells did not dry out. The plate was then placed under an inverted
microscope and UV light source to examine the cells for fluorescence.
Development of mouse monoclonal antibodies
Using 250 μg of the purified NSP2 protein mixed with an equal volume of water-in-oil
adjuvant (Seppic Montanide ISA 50 V2; Seppic, France), 3 ten-week-old specific pathogen-free
mice were immunized intraperitoneally 4 times in three-week intervals. After the final
immunization, the mice’s spleen cells were harvested and fused with NS-1 myeloma cells using
50% polyethylene glycol (GIBCO, Grand Island, NY). They were then grown in the present of
hypoxanthine-aminopterin-thymidine (HAT) media in order to select for only viable hybridoma
clones. The cell culture supernatant was then screened using NSP2 S-tag ELISA and IFA to
determine which clones produced antibodies specific to the PRRSV MLVΔ23-S tag antigen (as
described in respective sections above). Those clones which were positive were then subcloned
using limiting dilution in order to isolate monoclones. They were screened a final time using
NSP2 S-tag ELISA, IFA, and Western blotting (as described in respective sections above). These
monoclones were then isotyped using their culture fluids on a lateral-flow immunoglobulin
typing kit (Serotec; Raleigh, NC).

Development of rabbit polyclonal antisera
Two 4-month-old rabbits were immunized with a 150 μg dose of PRRSV NSP2 S-tag
antigen mixed in an equal volume with water-in-oil adjuvant (Seppic Montanide; Seppic,
France). The immunization was given both subcutaneously and intramuscularly in 4 separate
locations. Immunization was repeated three times at three-week intervals. Rabbits were then
euthanized, and their blood was collected via cardiac puncture. Their sera were tested via IFA,
ELISA, and Western blot to determine if they had antibodies against PRRSV NSP2 S-tag.
Animal studies were approved by the South Dakota State University Institutional Animal Care
and Use Committee (17-066A Mice; 17-067A Rabbits).

Results
Expression of the PRRSV NSP2 S-tag protein
After running the PRRSV S-tag protein on a polyacrylamide gel, the gel was cut into two
halves. The first half was stained using Coomassie blue (Figure 2B) while the second half
underwent Western blotting (Figure 2A). The Coomassie blue staining allowed visualization of
the proteins while Western blotting revealed the specificity of the PRRSV S-Tag protein, which
contained a histidine label, to an anti-histidine monoclonal antibody. Overexpression of the
protein was completed at a concentration of 1.5 mg/mL and showed a level of purification at
90%.
Development of mouse monoclonal antibodies
Initial screening of the PRRSV MLVΔ23-S tag hybridomas following the fusion resulted in
6 primary wells. These primaries were cloned to limiting dilution and subclones underwent

secondary screening via ELISA and IFA. Based on secondary screening, subclones were selected
to be expanded. The final expanded clones were screened a final time via ELISA, IFA (Figure 3),
and Western blotting (Figure 4). Each of the monoclones were also isotyped. All monoclones
with an IgM isotype were positive via ELISA and Western blot but were negative via IFA.
However, all of the IgG1 isotype monoclones were positive via ELISA, IFA, and Western blot.
Compiled data involving isotype and reactivity to ELISA, IFA, and Western blot of 18
monoclones is provided in Table 1.
Development of rabbit polyclonal antisera
150 mL of whole blood was collected via cardiac stick from the two New Zealand Red
rabbits after immunization with PRRSV NSP2 S-tag antigen. The blood was spun down then the
serum (77 mL) was removed and titered using ELISA and IFA (Figure 4). The results of this titer
are listed in Table 2.

PRRSV MLVΔ23-S tag Monoclone
Number

Isotype

16-63
16-75
84-92
84-94
84-99
84-103
84-106
84-110
84-113
142-13-46
142-36-13
142-36-16
142-36-120
142-36-123
142-206-26
142-206-40
142-306-45
205-346

IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgG1
IgM

Reactivity
ELISA IFA Western Blot
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Table 1. Monoclonal antibody reactivity. Eighteen hybridoma clones.
Immunoreactivity for each clone was tested via ELISA, IFA, and Western blotting.
Clones which showed positive immunoreactivity are indicated by a “ + ” while those
which were negative are indicated by a “ - ”.

Rabbit serum-antibody titer determination
(testing platform)
IFA
ELISA

Antibody Titer
Rabbit A
1/1,200
1/10,000

Antibody Titer
Rabbit B
1/1,600
1/12,000

Table 2. PRRSV NSP2 S-tag rabbit antisera antibody titers. Sera collected from two
New Zealand Red rabbits were titered via IFA and ELISA, these are the results.

2A

2B

25 kDa

Figure 2. Western detection & Coomassie blue staining of PRRSV NSP2 S-tag
protein. After protein purification, 100 μg of PRRSV NSP2 S-tag was run on a
polyacrylamide gel using electrophoresis. Half of the gel underwent Western blotting
(Figure 2A) while the other half was Coomassie blue stained (Figure 2B).

142-13-46

142-36-120

142-206-45

Figure 3. Immunofluorescent staining of PRRSV MLVD23S -infected MARC-145 cells.
Cell culture supernatant was taken from monoclones to stain infected MARC-145
cells. The above images show IFA-positive results from 3 individual monoclones.

M

1

2

3

4

5

6

Figure 4. Western blotting of PRRSV NSP2 S-tag protein. Six mouse monoclones
were subjected to Western blot detection. All six were shown to recognize the 25
kDa purified PRRSV NSP2 S-tag protein. Chromogenic (4-chloro-1-napthol) detection
method was used after probing with a peroxidase-labeled, isotype-specific, antimouse antibody.
(M) Marker; (1) mAb 142-13-39 IgG1; (2) mAb 142-36-120 IgG1; (3) mAb 142-206-45
IgG1; (4) mAb 205-346 IgM; (5) mAb 16-75 IgM; (6) mAb 84-99 IgM.

Rabbit A

Heterologous Rabbit Serum
Control

Rabbit B

Rabbit B 400X

Figure 5. Immunofluorescent staining of PRRSV MLVD23S -infected MARC-145
cells with rabbit polyclonal antisera. Rabbit A exhibited titers at 1/1200 while
Rabbit B exhibited titers at 1/1600.

Discussion
PRRSV has had a major economic effect on the swine industry since its emergence in the
late 1980’s and early 1990’s [1]. It causes a significant reduction in the number of piglets which
survive to weaning as well as an increase in secondary infections, reduction in growth
efficiency, and even death in growing-finishing pigs. These losses combined are estimated to
cost the swine industry around 560 million dollars annually [3]. A successful DIVA test
(differentiating infected from vaccinated animals) will provide a tool necessary to move the
industry one step closer to the eradication of PRRSV. Therefore, our primary objective of this
study was to develop monoclonal and polyclonal antibodies which could be used in further
research of a DIVA vaccine and accompanying diagnostic test.
We produced 18 mouse hybridoma monoclones against the PRRSV MLVΔ23-S tag
antigen. These monoclones were isotyped and their immunoreactivity was tested via ELISA, IFA,
and Western blot. All clones from the 142 series were IgG1 and immunoreactive via ELISA, IFA,
and Western blot. Clones from the 16, 82, and 205 series were IgM and immunoreactive via
ELISA and Western blot, but not IFA. This tells us that clones from the 142 series are able to
detect both linear and conformational epitopes while clones from the 16, 82, and 205 series
can only detect linear epitopes. In addition to the 18 monoclonal hybridoma clones, 75 mL of
anti-PRRSV NSP2 S-tag rabbit polyclonal antisera was collected from two rabbits: Rabbit A and
Rabbit B. It was tested via ELISA, IFA, and Western blot and found to have 1/1200 titers (Rabbit
A) and 1/1600 titers (Rabbit B). 500 μL of recombinant/purified PRRSV NSP2 S-tag protein was
also produced.

Purified PRRSV NSP2 S-tag protein can be used for future DIVA ELISA test development
and can provide a positive control for future Western blot development. Both monoclonal and
polyclonal antibodies can be used in future studies to validate DIVA IFA, ELISA, and Western
blot assays or to develop a DIVA Fluorescent Microsphere Immunoassay (FMIA).

Conclusion
The monoclonal and polyclonal antibodies produced in this study against PRRSV
MLVΔ23-S tag antigen are currently being used as reagents in development of a DIVA test for
PRRSV. A successful DIVA test for PRRSV could positively impact the swine industry and move us
one step closer to the eradication of PRRSV.
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